

(uPA), tissue type plasminogen activator (tPA), plasma kallikrein, factor XI<sub>a</sub>, HGKI and prostatic specific antigen (PSA).

A2 5. (Amended) A monoclonal antibody according to claim 1, wherein said inhibitor is protein C inhibitor (PCI) or  $\alpha_1$ -antitrypsin.

6. (Amended) A method for preparation of a monoclonal antibody as defined in claim 1, wherein an animal is immunised with a mixture of

- i) a complex between a serine proteinase and an inhibitor thereof, and
- ii) a cleaved form of said inhibitor, followed by screening for and isolation of said monoclonal antibody.

A3 8. (Amended) A method for monitoring the activity of systems involving protein C inhibitor, wherein a monoclonal antibody as defined in claim 1 is used in an immunoassay.

A4 15. (Amended) A method for diagnosis of venous thrombosis, arterial thrombosis, embolism, coronary infarction, disseminated intravascular coagulation or disorders involving lupus anticoagulants, wherein a monoclonal antibody according to claim 1 is utilised.

003300-816-001

A4  
16. (Amended) A method for diagnosis of venous thrombosis, arterial thrombosis, embolism, coronary infarction, disseminated intravascular coagulation or disorders involving lupus anticoagulants, wherein a method according to claim 8 is utilised.

---

A5  
19. (Amended) A kit for qualitative or quantitative determination of the activity of systems involving protein C inhibitor comprising a monoclonal antibody according to claim 1.

---

003300-816  
Please cancel Claims 17 and 18 without prejudice.

Please add the following new Claims 20 to 26.

---

A6  
20. (New) A monoclonal antibody according to claim 2, wherein said serine proteinase is selected from the group consisting of activated protein C (APC), thrombin, coagulation factor X<sub>a</sub>, trypsin, chymotrypsin, urokinase plasminogen activator (uPA), tissue type plasminogen activator (tPA), plasma kallikrein, factor XI<sub>a</sub>, HGKI and prostatic specific antigen (PSA).

21. (New) A monoclonal antibody according to claim 2, wherein said inhibitor is protein C inhibitor (PCI) or  $\alpha_1$ -antitrypsin.

22. (New) A method for preparation of a monoclonal antibody as defined in claim 2, wherein an animal is immunised with a mixture of

- AL
- i) a complex between a serine proteinase and an inhibitor thereof, and
  - ii) a cleaved form of said inhibitor, followed by screening for and isolation of said monoclonal antibody.

23. (New) A method for monitoring the activity of systems involving protein C inhibitor, wherein a monoclonal antibody as defined in claim 2 is used in an immunoassay.

24. (New) A method for diagnosis of venous thrombosis, arterial thrombosis, embolism, coronary infarction, disseminated intravascular coagulation or disorders involving lupus anticoagulants, wherein a monoclonal antibody according to claim 2 is utilised.

25. (New) A method for diagnosis of venous thrombosis, arterial thrombosis, embolism, coronary infarction, disseminated intravascular coagulation or disorders involving lupus anticoagulants, wherein a method according to claim 2 is utilised.

26. (New) A kit for qualitative or quantitative determination of the activity of systems involving protein C inhibitor comprising a monoclonal antibody according to claim 2.

---